

The Development of Pharmacoeconomy Guidelines in Indonesia

Ahmad Fuad Afdhal, Ph. D*

Presented at 7th ISPOR Asia-Pacific Conference
Singapore 3-6 September 2016

*Center for Socio-Economic Studies in Pharmacy, Jakarta, Indonesia

- The introduction of Pharmacoeconomy course in one School of Pharmacy in Jakarta
- The establishment of ISPOR Indonesia Chapter
- The release of a textbook of Pharmacoeconomy in Bahasa Indonesia
- Seminar and workshop in Pharmacoeconomy

BACKGROUND (1)

- The first printing of ISPOR Terminology book in Bahasa Indonesia
- Master Program in Pharmacoeconomy
- The increase in number of School of Pharmacy which has offered Pharmacoeconomy course

BACKGROUND (2)

- Directorate General of Pharmaceutical Services and Medical Devices of the Ministry of Health of Republic of Indonesia on 15th September 2011 decided to appoint a team to design and construct the 1st Pharmacoeconomy Guidelines for Indonesia.
- This PE Guidelines had been decided to be used for internal government institutions only.

INDONESIA PE GUIDELINES TEAM

- Review all existing national pharmacoeconomy guidelines
- Excerpts of those pharmacoeconomy guidelines
- Make framework of pharmacoeconomy guidelines

METHODS

- Systematic of the content
- The content itself
- Panel Discussion for the content
- Resume of the panel discussion

DEVELOPMENT PROCESS

- Senior consultants who are expert in pharmacoeconomy
- Officers from the Office of Ministry of Health
- Researchers from selected Universities
- Practitioners of government hospitals

PANEL DISCUSSION TEAM

- Theoretical review
- Perspective of Pharmacoeconomy evaluations
- Target users
- Comparisons
- Technique analyses

CONTENT OF PE GUIDELINES (1)

- Study design
- Strategy of implementation
- Implementation of Pharmacoeconomy techniques
- References

CONTENT OF PE GUIDELINES (2)

- Costs containment
- Optimize allocation of scarce healthcare resources

GOALS OF PE GUIDELINES

- Powerful marketing tool for targeting healthcare payers
- Improve patient access to cost-effective drugs

BENEFITS OF PE GUIDELINES

- In the near future PE Guidelines should be a path for a submission requirement for all pharmaceutical products.

FUTURE DEVELOPMENT (1)

- PE Guidelines should be a requirement basis for pharmaceutical products reimbursement to Universal Health Coverage

FUTURE DEVELOPMENT (2)

- Therapeutic value
- Market price
- Clinical effectiveness
- Budget impact
- Cost-effectiveness from the perspective of Universal Health Coverage

CRITERIA FOR REIMBURSEMENT

- Study design
- Calculation of costs
- Time horizon
- Valuation of outcomes

OTHER IMPORTANT ASPECTS FOR PE GUIDELINES (1)

- Modeling
- Handling uncertainty
- Discount rate

OTHER IMPORTANT ASPECTS FOR PE GUIDELINE (2)

Thank you for your kind attention.